Literature DB >> 1496399

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

P S Linsley1, P M Wallace, J Johnson, M G Gibson, J L Greene, J A Ledbetter, C Singh, M A Tepper.   

Abstract

In vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7 with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig suppressed responses to a second immunization. Thus, costimulation by B7 is important for humoral immune responses in vivo, and interference with costimulation may be useful for treatment of antibody-mediated autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1496399     DOI: 10.1126/science.1496399

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  187 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

4.  The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury.

Authors:  M Takada; A Chandraker; K C Nadeau; M H Sayegh; N L Tilney
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

5.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Authors:  L A Turka; P S Linsley; H Lin; W Brady; J M Leiden; R Q Wei; M L Gibson; X G Zheng; S Myrdal; D Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 6.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

7.  Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.

Authors:  Soosan Ghazizadeh; Li T Huang; Weibing Zhang
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 8.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

9.  Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.

Authors:  R Belani; G J Weiner
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

10.  Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats.

Authors:  Yongzhu Jin; Qingyin Zhang; Jie Hao; Xiang Gao; Yinglu Guo; Shusheng Xie
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.